Neuro-Oncology Committee
Meeting Agenda

Chair: Evanthia Galanis, MD

Welcome – Overview
E. Galanis

Active Protocols and Concepts in Development

Newly Diagnosed GBM

N0874 Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic Acid) [SAHA] Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma (Completed)
E. Galanis/P. Wen

N0877 Phase I Randomized Phase II Trial of Either Dasatinib or Placebo Combined with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM) (Accrual goal met on 12/6/13-ASCO presentation)
E. Galanis

Phase I/II Study of AZD1775 with Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma
B. Alexander

A071102: Randomized Trial of ABT-888 or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed GBM with MGMT Promoter Hypermethylation
J. Sarkaria

Individualized Screening trial of Innovative Glioblastoma Therapy (INSiGHt)
B. Alexander

A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 in Newly Diagnosed Glioblastoma Following Resection and Chemoradiation.
P. Wen
**Recurrent GBM**

N0872 Phase I Randomized Phase II Double Blinded Study of Either Dasatanib or Placebo Combined with Bevacizumab in Recurrent Glioblastoma (Accrual goal met on 3/27/14, ASCO presentation)  
E. Galanis

A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPCC-96) NSC #725085, BB IND# Pending) Vaccine Given with Bevacizumab versus Bevacizumab alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)  
E. Galanis/ E. Horvath

N1174: Phase I/Randomized Comparative Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab alone in Bevacizumab-Naive Patients with Recurrent Glioblastoma Multiforme  
E. Galanis/P. Wen

**Anaplastic Gliomas – Newly Diagnosed**

N0577 Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma  
K. Jaeckle

EORTC 26053-22054 Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial  
K. Jaeckle

**Low Grade Gliomas**

E3F05 Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas (Temp. Closed)  
D. Schiff

**Meningiomas**

A071401: Phase II Trial of SMO/AKT Inhibitors in Progressive Meningiomas with SMO/AKT Mutations  
P. Brastianos

**Craniopharyngiomas**

A071501: Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas  
P. Brastianos
Brain Metastases

N0574 A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) (Accrual goal met on 11/8/13, ASCO presentation)  

P. Brown

N017C A Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy In Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases  

E. Sulman

Molecularly-driven Trial in Brain Metastases  

P. Brastianos

Symptom Control

A221101: A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma Multiforme  

A. Porter

A221208: Bevacizumab vs. Steroids (BeSt) for Radionecrosis After Radiosurgery: A Randomized Phase II Trial  

C. Chung/ E. Sulman

Neuro-Oncology Imaging Subcommittee

Introduction to the Neuro-Oncology Imaging Subcommittee  

T. Kaufmann